Pathology Department, National Liver Institute, Menoufia University, Shebin Elkom, Menoufia, Egypt.
Radiology Department, Faculty of Medicine, Benha University, Benha, Egypt.
World J Surg Oncol. 2022 Sep 19;20(1):298. doi: 10.1186/s12957-022-02764-2.
Hepatocellular carcinoma (HCC) remains a major health problem despite the emergence of several preventive and therapeutic modalities. HCC has heterogeneous and wide morpho-molecular patterns, resulting in unique clinical and prognostic criteria. Therefore, we aimed to study the clinical and pathological criteria of HCC to update the morpho-molecular classifications and provide a guide to the diagnosis of this disease.
Five hundred thirty pathologically analyzed HCC cases were included in this study. The clinical and survival data of these cases were collected.
Hepatitis C virus is still the dominant cause of HCC in Egypt. Post-direct-acting antiviral agent HCC showed an aggressive course compared to interferon-related HCC. Old age, male gender, elevated alpha-fetoprotein level, tumor size, and background liver were important prognostic parameters. Special HCC variants have characteristic clinical, laboratory, radiological, prognostic, and survival data. Tumor-infiltrating lymphocytes rather than neutrophil-rich HCC have an excellent prognosis.
HCC is a heterogenous tumor with diverse clinical, pathological, and prognostic parameters. Incorporating the clinicopathological profile per specific subtype is essential in the treatment decision of patients with HCC.
This was a retrospective study that included 530 HCC cases eligible for analysis. The cases were obtained from the archives of the Pathology Department, during the period between January 2010 and December 2019. Clinical and survival data were collected from the patients' medical records after approval by the institutional review board (IRB No. 246/2021) of Liver National Institute, Menoufia University. The research followed the guidelines outlined in the Declaration of Helsinki and registered on ClinicalTrials.gov (NCT05047146).
尽管出现了多种预防和治疗方法，肝细胞癌 (HCC) 仍然是一个主要的健康问题。HCC 具有异质性和广泛的形态-分子模式，导致独特的临床和预后标准。因此，我们旨在研究 HCC 的临床和病理标准，以更新形态-分子分类，并为该疾病的诊断提供指导。
本研究纳入了 530 例经病理分析的 HCC 病例。收集了这些病例的临床和生存数据。
丙型肝炎病毒仍然是埃及 HCC 的主要病因。与干扰素相关的 HCC 相比，直接作用抗病毒药物治疗后的 HCC 表现出侵袭性病程。年龄较大、男性、甲胎蛋白水平升高、肿瘤大小和背景肝脏是重要的预后参数。特殊的 HCC 变体具有特征性的临床、实验室、影像学、预后和生存数据。肿瘤浸润淋巴细胞而不是富含中性粒细胞的 HCC 具有良好的预后。
HCC 是一种具有多种临床、病理和预后参数的异质性肿瘤。结合特定亚型的临床病理特征对于 HCC 患者的治疗决策至关重要。
这是一项回顾性研究，纳入了 530 例符合分析条件的 HCC 病例。这些病例是从 2010 年 1 月至 2019 年 12 月期间病理学系档案中获得的。在机构审查委员会 (IRB 编号 246/2021) 批准后，从患者的病历中收集了临床和生存数据，Liver National Institute，Menoufia University。该研究遵循赫尔辛基宣言的指导原则，并在 ClinicalTrials.gov (NCT05047146) 上注册。
